修订版PROPELLER用于3T前列腺T2加权成像:对病灶检出和PI-RADS分类的影响
前瞻性评估50例患者55个可疑病灶的3T MRI,以MRI引导活检病理为参考,比较修订版PROPELLER(RevPROP)与快速自旋回波(TSE)T2WI。RevPROP检出41/41例癌和54/55个病灶,TSE检出39/41例癌和51/55个病灶;RevPROP伪影更少、图像质量更高,PI-RADS评分和病灶大小无显著差异。
要点
- RevPROP检出全部41例癌和54/55个可疑病灶,TSE检出39/41例癌和51/55个病灶。
- RevPROP伪影更少且图像质量更高(均p < 0.001),基于两种序列的PI-RADS评分无显著差异。
- RevPROP病灶T2信号强度更高、T2对比度更低(均p < 0.001),但未影响诊断质量。
核心结论
- 在前列腺癌检出方面,RevPROP在运动稳健性、图像质量和病灶检出率上优于TSE,作者认为RevPROP可能作为T2WI的替代序列。
研究设计与样本
- 前瞻性研究,纳入50例患者共55个可疑病灶,在3T MR上采集T2 RevPROP、T2 TSE、扩散加权成像、动态对比增强和MR波谱,以MRI引导活检后组织病理学为参考标准。
关键影像表现/征象
- RevPROP图像伪影更少且图像质量更高(均p < 0.001)。
- RevPROP上病灶T2信号强度更高、病灶T2对比度更低(均p < 0.001)。
- 病灶大小在RevPROP与TSE间无显著差异(p = 0.105)。
诊断标准与关键数值
- RevPROP检出41/41例癌(100%)和54/55个可疑病灶(98.2%)。
- TSE检出39/41例癌(95.1%)和51/55个可疑病灶(92.7%)。
- 基于RevPROP与TSE的单个PI-RADS评分和总体PI-RADS评分均无显著差异(p = 0.106和p = 0.107)。
临床应用与阅片要点
- RevPROP可作为前列腺T2WI的替代序列,其运动稳健性和图像质量优于TSE。
- RevPROP上病灶T2对比度较低,但原文报告未影响其诊断质量,判读PI-RADS评分时与TSE无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate revised PROPELLER (RevPROP) for T2-weighted imaging (T2WI) of the prostate as a substitute for turbo spin echo (TSE).
MATERIALS AND METHODS: Three-Tesla MR images of 50 patients with 55 cancer-suspicious lesions were prospectively evaluated. Findings were correlated with histopathology after MRI-guided biopsy. T2 RevPROP, T2 TSE, diffusion-weighted imaging, dynamic contrast enhancement, and MR-spectroscopy were acquired. RevPROP was compared to TSE concerning PI-RADS scores, lesion size, lesion signal-intensity, lesion contrast, artefacts, and image quality.
RESULTS: There were 41 carcinomas in 55 cancer-suspicious lesions. RevPROP detected 41 of 41 carcinomas (100%) and 54 of 55 lesions (98.2%). TSE detected 39 of 41 carcinomas (95.1%) and 51 of 55 lesions (92.7%). RevPROP showed fewer artefacts and higher image quality (each p < 0.001). No differences were observed between single and overall PI-RADS scores based on RevPROP or TSE (p = 0.106 and p = 0.107). Lesion size was not different (p = 0.105). T2-signal intensity of lesions was higher and T2-contrast of lesions was lower on RevPROP (each p < 0.001).
CONCLUSION: For prostate cancer detection RevPROP is superior to TSE with respect to motion robustness, image quality and detection rates of lesions. Therefore, RevPROP might be used as a substitute for T2WI.
KEY POINTS: • Revised PROPELLER can be used as a substitute for T2-weighted prostate imaging. • Revised PROPELLER detected more carcinomas and more suspicious lesions than TSE. • Revised PROPELLER showed fewer artefacts and better image quality compared to TSE. • There were no significant differences in PI-RADS scores between revised PROPELLER and TSE. • The lower T2-contrast of revised PROPELLER did not impair its diagnostic quality.
引用
- Meier-Schroers M, Marx C, Schmeel FC, et al. Revised PROPELLER for T2-weighted imaging of the prostate at 3 Tesla: impact on lesion detection and PI-RADS classification. Eur Radiol. 2017. PMID: 28687915. doi:10.1007/s00330-017-4949-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。